Verloh N, Haimerl M, Zeman F, Schlabeck M, Barreiros A, Loss M, Schreyer A G, Stroszczynski C, Fellner C, Wiggermann P
Department of Radiology, University Hospital Regensburg, 93042, Regensburg, Germany,
Eur Radiol. 2014 May;24(5):1013-9. doi: 10.1007/s00330-014-3108-y. Epub 2014 Feb 16.
The purpose of this study was to evaluate the usefulness of Gd-EOB-DTPA-enhanced 3-T MRI to determine the hepatic functional reserve expressed by the model for end-stage liver disease (MELD) score.
A total of 121 patients with normal liver function (NLF; MELD score ≤ 10) and 29 patients with impaired liver function (ILF; MELD score > 10) underwent contrast-enhanced MRI with a hepatocyte-specific contrast agent at 3T. T1-weighted volume interpolated breath-hold examination (VIBE) sequences with fat suppression were acquired before and 20 min after contrast injection. Relative enhancement (RE) between plain signal intensity and contrast-enhanced signal intensity was calculated and was used to determine Gd-EOB-DTPA uptake into the liver parenchyma for patients with different MELD scores.
RE differed significantly (p ≤ 0.001) between patients with NLF (87.2 ± 29.5 %) and patients with ILF (45.4 ± 26.5 %). The optimal cut-off value for RE to differentiate NLF from ILF was 47.7 % (AUC 0.87). This cut-off value showed a sensitivity of 82.8 % and a specificity of 92.7 % for the differentiation of the analysed groups.
Gd-EOB-DTPA uptake in hepatocytes is strongly affected by liver function. Gd-EOB-DTPA-enhanced MRI and assessment of RE during the hepatobiliary phase (HBP) may serve as a useful image-based test in liver imaging for determining regional and global liver function.
Hepatic uptake of Gd-EOB-DTPA is strongly affected by liver function. Relative enhancement during HBP in GD-EOB-DTPA MRI correlates with the MELD score. Assessment of relative enhancement may help improve treatment in routine clinical practice.
本研究旨在评估钆塞酸二钠(Gd-EOB-DTPA)增强3T磁共振成像(MRI)用于确定终末期肝病模型(MELD)评分所表达的肝脏功能储备的效用。
121例肝功能正常(NLF;MELD评分≤10)和29例肝功能受损(ILF;MELD评分>10)的患者在3T下行肝细胞特异性对比剂增强MRI检查。在注射对比剂前及注射后20分钟采集脂肪抑制的T1加权容积内插屏气检查(VIBE)序列。计算平扫信号强度与对比增强信号强度之间的相对增强(RE),并用于确定不同MELD评分患者肝脏实质内钆塞酸二钠的摄取情况。
NLF患者(87.2±29.5%)与ILF患者(45.4±26.5%)的RE差异有统计学意义(p≤0.001)。区分NLF与ILF的RE最佳截断值为47.7%(曲线下面积0.87)。该截断值对分析组的区分显示出82.8%的敏感性和92.7%的特异性。
肝细胞对钆塞酸二钠的摄取受肝功能的强烈影响。钆塞酸二钠增强MRI及肝胆期(HBP)RE评估可作为肝脏成像中基于图像的有用检查,用于确定局部和整体肝功能。
钆塞酸二钠的肝脏摄取受肝功能的强烈影响。钆塞酸二钠MRI肝胆期的相对增强与MELD评分相关。相对增强评估可能有助于改善常规临床实践中的治疗。